Evidence map›Paper›PMID 40636075›Full record

ArticleJournal of diabetes research2025

Network Pharmacology and Serum Nontargeted Metabolomics Reveal the Protective Effects of Propionate Against Liver Damage Induced by a High-Fat and AGE-Rich Diet in Diabetic Mice.

Liang Wu, Jiajun Tan, Wen Sun, Xueyun Dong, Jiayuan He, Asmaa Ali, Min Chen, Leilei Zhang, Pingping Wang

Abstract read
In one paragraph

Article in Journal of diabetes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liang WuDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.ORCID https://orcid.org/0000-0002-8241-2433
Jiajun TanDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.ORCID https://orcid.org/0009-0005-6388-2543
Wen SunJurong Hospital Affiliated to Jiangsu University, Zhenjiang, China.
Xueyun DongDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.ORCID https://orcid.org/0009-0003-2724-9033
Jiayuan HeHealth Testing Center, Zhenjiang Center for Disease Control and Prevention, Zhenjiang, China.ORCID https://orcid.org/0009-0008-5023-926X
Asmaa AliDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.ORCID https://orcid.org/0000-0002-7421-5085
Min ChenPublic Experiment and Service Center, Jiangsu University, Zhenjiang, China.
Leilei ZhangDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.ORCID https://orcid.org/0000-0001-6761-2368
Pingping WangDepartment of Laboratory Medicine, Taizhou Second People's Hospital, Taizhou, China.ORCID https://orcid.org/0009-0004-5597-4221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic liver injury is a leading cause of mortality in diabetes, with no specific treatment available. Sodium propionate (NaP) has anti-inflammatory and antioxidant properties, but its effectiveness in treating diabetic liver injury is still lacking research. The study employed network pharmacology to identify potential targets of NaP for Type 2 diabetes treatment, using oleic acid (OA) and advanced glycation end products (AGEs) to induce diabetic liver injury in HepG2 cells

Indexed as

Anti-Inflammatory AgentsDiabetes Mellitus, ExperimentalDiet, High-FatLiverLiver DiseasesPropionatesAnimalsAntioxidantsGlycation End Products, AdvancedHep G2 CellsHumansMaleMetabolomicsMiceMice, Inbred C57BLNetwork PharmacologyAnti-Inflammatory AgentsAntioxidantsGlycation End Products, AdvancedPropionatesautophagydiabetic liver injurynetwork pharmacologynontargeted metabolomicspropionate

Identifiers

PMID40636075
PMCPMC12240661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.